Kevin Young
2017
In 2017, Kevin Young earned a total compensation of $6.2M as Chief Operating Officer at Gilead Sciences, a 10% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,522,969 |
|---|---|
| Option Awards | $2,050,007 |
| Salary | $1,115,769 |
| Stock Awards | $1,366,772 |
| Other | $166,225 |
| Total | $6,221,742 |
Young received $2.1M in option awards, accounting for 33% of the total pay in 2017.
Young also received $1.5M in non-equity incentive plan, $1.1M in salary, $1.4M in stock awards and $166.2K in other compensation.
Rankings
In 2017, Kevin Young's compensation ranked 1,399th out of 14,666 executives tracked by ExecPay. In other words, Young earned more than 90.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,399 out of 14,666 | 91st |
Division Manufacturing | 479 out of 5,772 | 92nd |
Major group Chemicals And Allied Products | 125 out of 2,075 | 94th |
Industry group Drugs | 88 out of 1,731 | 95th |
Industry Biological Products, Except Diagnostic Substances | 17 out of 313 | 95th |
Source: SEC filing on March 26, 2018.
Young's colleagues
We found five more compensation records of executives who worked with Kevin Young at Gilead Sciences in 2017.